2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.35

PP02.35 - Prabhat Singh Malik

Pdf Summary

This study investigates young onset lung cancer (LC) in patients aged 40 years and below, treated between January 2018 and December 2023 at the All India Institute of Medical Sciences (AIIMS), New Delhi. Traditionally seen in older adults, LC in individuals under 40 is rare, constituting up to 6% in various studies. However, in this Northern India cohort, this demographic represented 11% of cases, highlighting a higher prevalence.<br /><br />The study involved 141 patients with a median age of 36, predominantly male (57.45%) and non-smokers (79.1%). The most common histological subtype was adenocarcinoma (80.85%). Notably, there was a significant presence of targetable genomic alterations, with ALK rearrangement in 34% of cases, ROS1 in 7.25%, and EGFR mutations in 35.51%.<br /><br />First-line systemic treatments included chemotherapy (62.9%), targeted therapy inhibitors (TKIs) (26.6%), and combinations. Patients who received TKI showed significantly better overall survival rates, with a median of 33 months compared to 11.2 months for those who did not.<br /><br />The study concludes that young onset LC is distinct with a higher prevalence of targetable genomic alterations. Therefore, identifying and using targeted therapy in this population is crucial for better outcomes.<br /><br />The findings emphasize a tailored approach to treatment, given the unique clinical and molecular profiles of young LC patients, differing from the elder LC demographic. This study highlights the need for more research to understand this subset of patients better and improve their management and survival outcomes, given the distinct genetic features and significant role of targeted therapies in their treatment regimen.

Keywords

young onset lung cancer

AIIMS New Delhi

adenocarcinoma

ALK rearrangement

ROS1

EGFR mutations

targeted therapy

TKI

genomic alterations

treatment outcomes